viewAnteris Technologies Ltd

Admedus transformative 2019 sets company up to drive value of ADAPT® portfolio

Total revenue for the company was $17.1 million, which includes $10.2 million from sales of ADAPT® products and $6.9 million of Infusion products.

Admedus Ltd - Admedus remains focused on ADAPT® single-piece 3D aortic valve after a transformative 2019 year
Admedus is set to begin its first-in-human surgical aortic valve replacement (SAVR) trial this quarter

Admedus Ltd (ASX:AHZ) remains focused on further developing its ADAPT® single-piece 3D aortic valve for the surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) markets after a transformative 2019 year.

While completing the divestment of non-core assets, Admedus has transitioned to become a structural heart company focused on the development of novel products using its proprietary ADAPT® tissue technology.

In a preliminary financial report for the period ending December 31, 2019, Admedus stated it was set to begin its pivotal first-in-human SAVR)trial of its 3D aortic valve this quarter.

Driving value in ADAPT® portfolio

Chief executive officer Wayne Paterson said: “2019 was a pivotal year for Admedus.

“The capital injection has enabled the company to concentrate on driving the value in its ADAPT® portfolio, reduce operating expenses and develop next-generation products for the structural heart market.”

2019 highlights

2019 included the following highlights:

  • Successful recapitalisation with the sale of distribution rights to CardioCel® and VascuCel® patch business to US-based LeMaitre Vascular Inc (including a $21.2 million upfront payment) and the part-divestment of the Infusion business for $6.3 million, resulting in a closing cash balance of $16.1 million;
  • Total revenue of $17.1 million for the 2019 financial year compared with $25.6 million in 2018. FY2019 revenue includes $10.2 million from sales of ADAPT® products and $6.9 million of Infusion products - reflecting the contribution from the Infusion business until its part-divestment in May 2019 and the patch business until its sale to LeMaitre in October 2019;
  • Gross profit for the group for the year was $8.3 million, representing a gross margin of 49% (in line with 2018);
  • Selling, general and administrative expenses (SG&A) reduced to $31.6 million from $34.3 million in the prior year following a significant reduction in global headcount. The full impact of this reduction will be reflected in the 2020 accounts; and
  • Net loss after tax reduced to $6.2 million compared with $24.7 million in 2018, including gains from the patch business sale as well as the part-divestment of the infusion business.

Quick facts: Anteris Technologies Ltd

Price: 3.61 AUD

Market: ASX
Market Cap: $21.34 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...



Anteris Technologies 'delivering on its goals despite pandemic'

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are...

on 6/7/20

2 min read